Results 1 to 10 of about 71,439 (210)

Erlotinib [PDF]

Reactions Weekly, 2020
Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing ...
Ahmed A, Abdelgalil, Hamad M, Al-Kahtani, Fahad I, Al-Jenoobi   +2 more
  +7 more sources

Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer: A Report of 92 Eases [PDF]

Chinese Journal of Lung Cancer, 2009
Background and objective Erlotinib, a selective inhibitor of epidermal growth factor receptor tyrosine kinase, has been approved effective in local advanced or metastatic non-small cell lung cancer (NSCLC).
Baohui HAN, Zhiqiang GAO, Chunlei SHI, Liwen XIONG, Huimin WANG, Aiqin GU   +5 more
doaj   +1 more source

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Cells, 2021
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs).
Nadiia Lypova, Susan M. Dougherty, Lilibeth Lanceta, Jason Chesney, Yoannis Imbert-Fernandez   +4 more
doaj   +1 more source

Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway

Frontiers in Oncology, 2021
BackgroundErlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, demonstrated therapeutic efficacy against pancreatic cancer.
Huiting Xu, Runzhi Chen, Qian Shen, Dongmei Yang, Hui Peng, Jin Tong, Qiang Fu   +6 more
doaj   +1 more source

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Current Research in Toxicology, 2021
Objective: To evaluate drug-drug interactions (DDIs) between gefitinib or erlotinib with fluoxetine, and/or losartan. Methods: Human pooled microsomes, supersomes, and cryopreserved human hepatocytes were used to monitor DDIs in vitro.
Thu-Lan T. Luong, Michael J. McAnulty, David L. Evers, Brian J. Reinhardt, Peter J. Weina   +4 more
doaj   +1 more source

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Thoracic Cancer, 2022
Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation‐positive (EGFR+) non‐small cell lung cancer (NSCLC ...
Yukio Hosomi, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto   +8 more
doaj   +1 more source

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

Diseases, 2023
The objective of this systematic review and meta-analysis was to assess and contrast the efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
Prashant Sakharkar, Sonali Kurup
doaj   +1 more source

Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer

Molecular Oncology, 2021
Erlotinib is highly effective in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. However, despite initial favorable responses, most patients rapidly develop resistance to erlotinib soon after the initial treatment. This study
Jieun Lee, Ahyoung Choi, Sung‐Yup Cho, Yukyung Jun, Deukchae Na, Ahra Lee, Giyong Jang, Jee Young Kwon, Jaesang Kim, Sanghyuk Lee, Charles Lee   +10 more
doaj   +1 more source

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. [PDF]

, 2015
We hypothesized that aberrations activating epidermal growth factor receptor (EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., cetuximab).
Bazhenova, Lyudmila, Greenberg, Jerry P, Kouznetsova, Valentina L, Kurzrock, Razelle, Stewart, David J, Tsigelny, Igor F, Wheler, Jennifer J   +6 more
core   +7 more sources

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

Advanced Science, 2023
Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low among patients with gastric cancer (GC).
Fangyuan Li, Junxian Yu, Tao Pan, Haoran Feng, Jianfang Li, Beiqin Yu, Zhiyuan Fan, Qingqing Sang, Mengdi Chen, Mingde Zang, Junyi Hou, Xiongyan Wu, Yingyan Yu, Yuan‐Yuan Li, Chao Yan, Zhenggang Zhu, Liping Su, Bingya Liu   +17 more
doaj   +1 more source